Oregon Health & Science University

Ventana Medical Systems, Inc.

Novartis Ag

Dana-farber-cancer Institute Inc.

Technische Universitat Munchen

Centre Hospitalier Régional Universitaire De Lille

Medvet Science Pty Ltd

Université Victor Segalen—bordeaux 2

University of Heidelberg

Brian Jay Druker

Michael S Barnes

Joe W Gray

Christophe Chefd'hotel

Thomas M Grogan

David Chafin

Benjamin C Stevens

Karl Eric Garsha

Kandavel Shanmugam

Esteban Roberts

Jonathan A Fletcher

Timothy Charles Hughes

Thomas Jacob

Franklin Ventura

Amie Corbin

Damien Ramunno-Johnson

Tania Vu

Tothu Tania Vu

Michael C Heinrich

Jeffrey Tyner

Elisabeth Buchdunger

George Daniel Demetri

Heikki Joensuu

Sandra Leta Silberman

Stephen Kurtz

Shannon K McWeeney

Justus Duyster

Elie Traer

Daniel Bottomly

Beth Wilmot

Nicola Long

Samantha Savage Stevens

Anna Reister Schultz

Martin Mueller

David Tuveson

Sasa Dimitrijevic

Renaud Capdeville

François-Xavier Mahon

Cristina Tognon

Gérald Marit

Catherine Roche Lestienne

Susan Branford

Zbigniew Rudzki

Michael Barnes

Joe Gray

Tothu (tania) Vu

Frank R Ventura

Karl E Garsha

Christophe Chefd´hotel

Claude Preudhomme

Thibaut Leguay

Christian Peschel

Christophe Barthe

Sebastian Kreil

Andreas Hochhaus

The present invention relates to useful methods of treating Acute Myeloid Leukemia (AML) in a human. in the presence of gene mutations.

Treatments for mutations in acute myeloid leukemia

Methods, systems, and apparatuses for detecting and describing heterogeneity in a cell sample are disclosed herein. A plurality of fields of view (FOV) are generated for one or more areas of interest (AOI) within an image of the cell sample are generated. Hyperspectral or multispectral data from each FOV is organized into an image stack containing one or more z-layers, with each z-layer containing intensity data for a single marker at each pixel in the FOV. A cluster analysis is applied to the image stacks, wherein the clustering algorithm groups pixels having a similar ratio of detectable marker intensity across layers of the z-axis, thereby generating a plurality of clusters having similar expression patterns.

Methods, systems, and apparatuses for quantitative analysis of heterogeneous biomarker distribution

Embodiments herein provide methods, apparatuses, and systems for detecting, monitoring, measuring, and/or characterizing the activity of phosphoproteins such as tyrosine kinases (TKs) and downstream proteins in TK signal transduction pathways (e.g., TK pathway proteins). In various embodiments, the methods, apparatuses, and systems may use nanoparticles, such as quantum dots (QD), to detect and/or characterize the abnormally overactive TK signaling pathways that underlie tumorgenesis and tumor progression. In various embodiments, the QD-based methods, apparatuses, and systems may have a sufficiently high degree of sensitivity to enable the identification of new TK signaling pathway markers, for example for use in diagnosing, staging, monitoring, and/or prognosing cancers, or in evaluating the efficacy of cancer therapeutics.

Methods apparatuses and systems for detecting and quantifying phosphoproteins

The present invention relates to isolated polypeptides which comprise an amino acid sequence consisting of a mutated functional Abl kinase domain, said mutated functional kinase domain being resistant to inhibition of its tyrosine kinase activity by N-[4-methyl-3-(4-pyridin-3-yl-pyrimidin-2-ylamino)-phenyl]-4-(4-methyl-piperazin-1-ylmethyl)-benzamide or a salt thereof, to the use of such polypeptides to screen for compounds which inhibit the tyrosine kinase activity of such polypeptides, to nucleic acid molecules encoding such polypeptides, to recombinant vectors and host cells comprising such nucleic acid molecules and to the use of such nucleic acid molecules in the production of such polypeptides for use in screening for compounds which inhibit the tyrosine kinase activity of such polypeptides.

Detection of gleevec resistance

Detection of gleevec resistant mutations

4-(4-methylpiperazin-1-ylmethyl)-N-[4-methyl-3-(4-pyridin-3-yl)pyrimidin-2-ylamino)phenyl]-benzamide of the formula Ior a pharmaceutically acceptable salt thereof can be used in the treatment of gastrointestinal stromal tumours.

Treatment of gastrointestinal stromal tumors

Growing community of inventors

Portland, OR, United States of America

Brian Jay Druker